Vicapsys Life Sciences Completes Reverse Merger with Stateline Distributors of Puerto Rico and Signs Definitive Agreement to Acquire NitroMist, Creating a Vertically Integrated Pharmaceutical Manufacturing and Distribution Platform Serving Federal, Tribal
Vicapsys Life Sciences (VICP) completed a reverse merger with Stateline Distributors, a Puerto Rico-based pharmaceutical wholesaler, and acquired NitroMist, a nitroglycerin product, for a $2.0 million convertible note. The company plans to acquire a 120,000 sq ft manufacturing facility in Puerto Rico to produce NitroMist and other products, aiming to serve federal and tribal markets.
How this was made
The 30-second read
Why it matters
The combined entity now controls wholesale distribution, federal contracting access, and a branded product, positioning it for growth in underserved government drug markets.
Market read
The deal creates a vertically integrated pharma distributor/manufacturer targeting federal, tribal, and veteran health markets, a niche with limited competition.
What to watch
Regulatory approval timeline for NitroMist relaunch and integration risks of the Puerto Rico facility.
Background
Vicapsys Life Sciences (OTC:VICP) announced the completion of its reverse merger with Stateline Distributors of Puerto Rico and an asset purchase of the NitroMist nitroglycerin product.
Ticker impact
Vicapsys Life Sciences completed a reverse merger with Stateline Distributors and signed a definitive agreement to acquire NitroMist, creating a new integrated pharma platform.
Potential upside as the combined entity gains federal contracting access and a product pipeline.
The deal is material for a micro‑cap OTC stock, but the financial scale is modest; market reaction will depend on execution risk.
Market effects
Creates a niche integrated distributor/manufacturer in federal and tribal drug markets, may inspire similar consolidations.
Strengthens pharma distribution presence in Puerto Rico and tribal 8(a) channels.
Limited to U.S. federal contracting niche; minimal global impact.
Counterpoint
The small scale and OTC status may limit liquidity and investor interest despite strategic benefits.
Key entities
- CompanyVicapsys Life Sciences, Inc.
OTC‑listed pharma platform completing reverse merger.
- CompanyStateline Distributors of Puerto Rico, Inc.
Specialty pharmaceutical wholesale distributor acquired in the merger.
- ProductNitroMist
FDA‑approved nitroglycerin lingual aerosol acquired by VICP.

